Competition is on the horizon for costly narcolepsy treatments
pharmaphorum
DECEMBER 14, 2022
But increased competition is on the horizon. In 2020, and in an attempt to abate the drawback, Jazz got FDA approval for Xywav, which is a mixture of calcium, magnesium, and potassium salts that contains 92% less sodium than Xyrem. Competition starts to heat up. Classic treatment options. Xyrem is one of three that has a patent.
Let's personalize your content